Y Intercept Hong Kong Ltd Invests $452,000 in Theravance Biopharma, Inc. $TBPH

Y Intercept Hong Kong Ltd purchased a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 40,943 shares of the biopharmaceutical company’s stock, valued at approximately $452,000.

A number of other hedge funds also recently made changes to their positions in TBPH. AQR Capital Management LLC bought a new position in Theravance Biopharma during the first quarter worth $101,000. R Squared Ltd lifted its position in Theravance Biopharma by 636.6% during the first quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 10,822 shares during the last quarter. Tabor Asset Management LP bought a new position in shares of Theravance Biopharma during the first quarter worth approximately $135,000. Ballentine Partners LLC grew its stake in shares of Theravance Biopharma by 9.3% in the second quarter. Ballentine Partners LLC now owns 14,315 shares of the biopharmaceutical company’s stock valued at $158,000 after acquiring an additional 1,221 shares in the last quarter. Finally, State of Wyoming raised its position in shares of Theravance Biopharma by 36.2% in the first quarter. State of Wyoming now owns 17,909 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 4,758 shares in the last quarter. 99.10% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. B. Riley began coverage on shares of Theravance Biopharma in a research report on Friday, September 12th. They issued a “buy” rating and a $28.00 target price for the company. Zacks Research downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 15th. Weiss Ratings restated a “hold (c)” rating on shares of Theravance Biopharma in a report on Wednesday, October 8th. Finally, Wall Street Zen raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Saturday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $23.00.

Theravance Biopharma Price Performance

Shares of NASDAQ:TBPH opened at $14.87 on Friday. The firm has a fifty day moving average price of $14.18 and a two-hundred day moving average price of $12.02. The company has a market cap of $748.85 million, a price-to-earnings ratio of 61.96 and a beta of 0.07. Theravance Biopharma, Inc. has a one year low of $7.90 and a one year high of $15.34.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.